newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  • Cogent Biosciences presented updated preclinical data for its pan KRAS(ON) inhibitor CGT1263 at the 2025 AACR-NCI-EORTC conference in Boston.
  • The company aims to file an Investigational New Drug (IND) application with the FDA for the program in 2026.
  • CGT1263 demonstrates picomolar activity against KRAS mutant cell lines with selectivity over HRAS and NRAS.
  • The prodrug CGT1815 showed superior efficacy in tumor growth inhibition studies for KRAS G12D and KRAS G12V mutations compared to RMC-6236.
  • CGT1263 and CGT1815 pharmacokinetic data were characterized across multiple species to optimize human performance.
  • Poster details include session B on October 24, 2025, with poster number B024.
  • Cogent's most advanced clinical program is bezuclastinib, a selective tyrosine kinase inhibitor targeting KIT D816V for systemic mastocytosis.
  • The company is also conducting a Phase 1 study of an FGFR2/3 inhibitor.
  • Additional pipeline candidates target mutations in ErbB2, PI3Kα, KRAS, and KIT exon 17.
  • Cogent Biosciences is headquartered in Waltham, MA, and Boulder, CO.